Docket No.: 1422-0720PUS1 Application No.: 10/582,323 Page 2 of 9

Art Unit 1623

Reply to Office Action of January 14, 2011

AMENDMENTS TO THE CLAIMS

1-11. (Cancelled).

(Currently Amended) A method for ameliorating or treating an inflammatory 12.

bowel disease, comprising

administering a composition comprising galactomannan as an agent in an amount

sufficient for lowering to lower the activity of myeloperoxidase and TNF-α to a patient suffering

from said inflammatory bowel disease, wherein said galactomannan is a degraded

galactomannan having an average molecular weight of from 8,000 to 50,000 and a viscosity of

10 mPa·s or less, as determined by 0.5 (w/v)% aqueous solution of the degraded galactomannan,

and produced by hydrolyzing guar gum with  $\beta$ -mannanase.

13. (Cancelled)

14. (Previously Presented) The method according to claim 12, wherein said

galactomannan is administered with a protein.

15. (Previously Presented) The method according to claim 14, wherein the protein is

one or more proteins selected from the group consisting of a soy protein, a milk protein, a yolk

protein, an albumen protein, a wheat protein and a degraded product thereof.

16. (Cancelled) Application No.: 10/582,323 Docket No.: 1422-0720PUS1
Art Unit 1623 Page 3 of 9

Art Unit 1623
Reply to Office Action of January 14, 2011

17. (Previously Presented) The method according to claim 14, wherein said composition is administered as a liquid food.

18-20. (Cancelled)

21. (Previously Presented) The method according to claim 12, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn's disease and intestinal Behçet disease.

22. (Previously Presented) The method according to claim 14, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis, Crohn's disease and intestinal Behçet disease.

23-25. (Canceled)

26. (Previously Presented) The method according to claim 12, wherein said composition comprises galactomannan and does not comprise arabinogalactan.

27-29. (Cancelled)

30. (Previously Presented) The method according to claim 12, wherein the degraded galactomannan is produced by a process consisting essentially of hydrolyzing guar gum with  $\beta$ -mannanase.

Application No.: 10/582,323

Art Unit 1623

Reply to Office Action of January 14, 2011

Docket No.: 1422-0720PUS1

Page 4 of 9

31. (Previously Presented) The method according to claim 12, wherein the degraded galactomannan is produced by hydrolyzing guar gum with  $\beta$ -mannanase without further chemical processing.